Targeting SNRNP200-Induced Splicing Dysregulation: A New Strategy for Immunotherapy in Glycolytic Triple-Negative Breast Cancer Background Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by extremely high recurrence and mortality rates. Despite significant recent advances in research on TNBC subty...

Epitope Prime Editing Shields Hematopoietic Cells from CD123 Immunotherapy: A Novel Therapeutic Strategy for Acute Myeloid Leukemia Research Background and Problem Statement Acute Myeloid Leukemia (AML) is a malignant blood disease characterized by the abnormal differentiation of myeloid hematopoietic stem and progenitor cells (HSPCs). Its incidenc...

Background Introduction Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with a five-year survival rate of less than 20%, and treatment options are extremely limited. Traditional targeted drug therapies, such as Sorafenib and other kinase inhibitors, have been used to treat HCC, but their efficacy is limited and diffi...

Fibrotic Response Induced by Anti-CSF-1R Treatment Promotes Glioblastoma Recurrence Background Introduction Glioblastoma (GBM) is a highly aggressive and malignant primary tumor of the central nervous system. Although current standard treatments include surgical resection, Temozolomide chemotherapy, and fractionated radiotherapy, the median surviva...

Fusobacterium nucleatum Promotes Anti-PD-1 Therapy in Microsatellite-Stable Colorectal Cancer Background Introduction With the rise of immune checkpoint blockade (ICB) therapy, a new dawn has emerged in cancer treatment. However, despite the approval of PD-1 targeting drugs (e.g., Pembrolizumab) for certain types of colorectal cancer (CRC) patients...